TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised Phase 3 Trial Of Accelerated Partial Breast Irradiation Using Intensity Modulated Radiotherapy Versus Whole Breast Irradiation
Brief Summary: The aim of this Phase 3 randomised trial is to compare the efficacy and safety of whole breast radiotherapy to accelerated partial breast irradiation using intensity-modulated radiotherapy technique in selected early breast cancer patients after breast conserving surgery.


Options:
A: Arm Label: Whole breast irradiation (WBI); Type: ACTIVE_COMPARATOR; Interventions: Radiation: Whole breast irradiation (WBI) | Arm Label: Partial breast irradiation (APBI); Type: EXPERIMENTAL; Interventions: Radiation: Accelerated partial breast irradiation (APBI) | Intervention Type: RADIATION; Name: Accelerated partial breast irradiation (APBI); Assigned to Arm(s): Partial breast irradiation (APBI) | Intervention Type: RADIATION; Name: Whole breast irradiation (WBI); Assigned to Arm(s): Whole breast irradiation (WBI)
B: Arm Label: APBI; Type: EXPERIMENTAL; Interventions: Radiation: Accelerated partial breast irradiation | Arm Label: EBRT; Type: ACTIVE_COMPARATOR; Interventions: Radiation: External beam whole breast irradiation | Intervention Type: RADIATION; Name: Accelerated partial breast irradiation; Assigned to Arm(s): APBI | Intervention Type: RADIATION; Name: External beam whole breast irradiation; Assigned to Arm(s): EBRT
C: Arm Label: ELIOT; Type: EXPERIMENTAL; Interventions: Radiation: intraoperative radiotherapy | Arm Label: EXTERNAL RT; Type: ACTIVE_COMPARATOR; Interventions: Radiation: external fractionated radiotherapy | Intervention Type: RADIATION; Name: external fractionated radiotherapy; Assigned to Arm(s): EXTERNAL RT | Intervention Type: RADIATION; Name: intraoperative radiotherapy; Assigned to Arm(s): ELIOT
D: Arm Label: Intra-operative radiotherapy; Type: EXPERIMENTAL; Interventions: Device: Intrabeam | Arm Label: Post-operative radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Post-operative radiotherapy | Intervention Type: DEVICE; Name: Intrabeam; Assigned to Arm(s): Intra-operative radiotherapy | Intervention Type: RADIATION; Name: Post-operative radiotherapy; Assigned to Arm(s): Post-operative radiotherapy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised Phase 3 Trial Of Accelerated Partial Breast Irradiation Using Intensity Modulated Radiotherapy Versus Whole Breast Irradiation
Brief Summary: The aim of this Phase 3 randomised trial is to compare the efficacy and safety of whole breast radiotherapy to accelerated partial breast irradiation using intensity-modulated radiotherapy technique in selected early breast cancer patients after breast conserving surgery.


Options:
A: Arm Label: Intra-operative radiotherapy; Type: EXPERIMENTAL; Interventions: Device: Intrabeam | Arm Label: Post-operative radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Post-operative radiotherapy | Intervention Type: DEVICE; Name: Intrabeam; Assigned to Arm(s): Intra-operative radiotherapy | Intervention Type: RADIATION; Name: Post-operative radiotherapy; Assigned to Arm(s): Post-operative radiotherapy
B: Arm Label: ELIOT; Type: EXPERIMENTAL; Interventions: Radiation: intraoperative radiotherapy | Arm Label: EXTERNAL RT; Type: ACTIVE_COMPARATOR; Interventions: Radiation: external fractionated radiotherapy | Intervention Type: RADIATION; Name: external fractionated radiotherapy; Assigned to Arm(s): EXTERNAL RT | Intervention Type: RADIATION; Name: intraoperative radiotherapy; Assigned to Arm(s): ELIOT
C: Arm Label: APBI; Type: EXPERIMENTAL; Interventions: Radiation: Accelerated partial breast irradiation | Arm Label: EBRT; Type: ACTIVE_COMPARATOR; Interventions: Radiation: External beam whole breast irradiation | Intervention Type: RADIATION; Name: Accelerated partial breast irradiation; Assigned to Arm(s): APBI | Intervention Type: RADIATION; Name: External beam whole breast irradiation; Assigned to Arm(s): EBRT
D: Arm Label: Whole breast irradiation (WBI); Type: ACTIVE_COMPARATOR; Interventions: Radiation: Whole breast irradiation (WBI) | Arm Label: Partial breast irradiation (APBI); Type: EXPERIMENTAL; Interventions: Radiation: Accelerated partial breast irradiation (APBI) | Intervention Type: RADIATION; Name: Accelerated partial breast irradiation (APBI); Assigned to Arm(s): Partial breast irradiation (APBI) | Intervention Type: RADIATION; Name: Whole breast irradiation (WBI); Assigned to Arm(s): Whole breast irradiation (WBI)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Case Series Clinical Study of the Reversal of the Anticoagulant Effects of Dabigatran by Intravenous Administration of 5.0g Idarucizumab (BI 655075) in Patients Treated Wtih Dabigatran Etexilate Who Have Uncontrolled Bleeding or Require Emergency Surgery or Procedures.RE-VERSE AD (A Study of the RE-VERSal Effects of Idarucizumab on Active Dabigatran) Trial
Brief Summary: Evaluate the reversal of the anticoagulant effects of dabigatran by IV administration of 5.0g idarucizumab in patients treated with dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures.


Options:
A: Arm Label: Acute Coronary Syndrome; Type: N/A; Interventions: Other: Thrombin generation assays, TEG and GTT | Intervention Type: OTHER; Name: Thrombin generation assays, TEG and GTT; Assigned to Arm(s): Acute Coronary Syndrome
B: Arm Label: Rivaroxaban 2.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban, Other: Standard of care for heart failure and coronary artery disease | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Other: Standard of care for heart failure and coronary artery disease | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban 2.5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: OTHER; Name: Standard of care for heart failure and coronary artery disease; Assigned to Arm(s): Placebo, Rivaroxaban 2.5 mg
C: Arm Label: idarucizumab; Type: EXPERIMENTAL; Interventions: Drug: idarucizumab | Intervention Type: DRUG; Name: idarucizumab; Assigned to Arm(s): idarucizumab
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: apixaban | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: apixaban; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Randomized Study Comparing the Effects of Selective Laser Trabeculoplasty and Travoprost on the Circadian Intraocular Pressure Variation
Brief Summary: The investigators conduct this study to access the effect of selective laser trabeculoplasty on 24-hour circadian tension curves of patients with open-angle glaucoma, normal tension glaucoma and ocular hypertension. This treatment effect is compared with that of the prostaglandin analogue, travoprost.


Options:
A: Arm Label: Selective laser trabeculoplasty; Type: EXPERIMENTAL; Interventions: Device: Selective laser trabeculoplasty | Arm Label: Travoprost; Type: ACTIVE_COMPARATOR; Interventions: Drug: Travoprost | Intervention Type: DEVICE; Name: Selective laser trabeculoplasty; Assigned to Arm(s): Selective laser trabeculoplasty | Intervention Type: DRUG; Name: Travoprost; Assigned to Arm(s): Travoprost
B: Arm Label: Argon laser trabeculoplasty; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Argon laser trabeculoplasty, Procedure: Selective laser trabeculoplasty | Arm Label: selective laser trabeculoplasty; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Argon laser trabeculoplasty, Procedure: Selective laser trabeculoplasty | Intervention Type: PROCEDURE; Name: Argon laser trabeculoplasty; Assigned to Arm(s): Argon laser trabeculoplasty, selective laser trabeculoplasty | Intervention Type: PROCEDURE; Name: Selective laser trabeculoplasty; Assigned to Arm(s): Argon laser trabeculoplasty, selective laser trabeculoplasty
C: Intervention Type: DRUG; Name: prednisolone acetate 1%; Assigned to Arm(s): N/A
D: Arm Label: Direct Selective Trabeculoplasty; Type: EXPERIMENTAL; Interventions: Device: Direct Selective Trabeculoplasty | Arm Label: Selective Trabeculoplasty; Type: ACTIVE_COMPARATOR; Interventions: Device: Selective Trabeculoplasty | Intervention Type: DEVICE; Name: Direct Selective Trabeculoplasty; Assigned to Arm(s): Direct Selective Trabeculoplasty | Intervention Type: DEVICE; Name: Selective Trabeculoplasty; Assigned to Arm(s): Selective Trabeculoplasty

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-centre, Feasibility, Cluster Randomised Controlled Trial Comparing Restrictive Versus Liberal Blood Transfusion Strategies in Adult Patients Admitted With Acute Upper Gastrointestinal Bleeding
Brief Summary: Aim: To evaluate the feasibility and safety of a restrictive versus liberal red blood cell (RBC) transfusion policy in adult patients admitted with Acute Upper Gastrointestinal Bleeding (AUGIB) in order to inform the design of a definitive phase III randomised controlled trial.


Options:
A: Arm Label: Liberal; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Liberal transfusion strategy | Arm Label: Restrictive; Type: EXPERIMENTAL; Interventions: Behavioral: Restrictive transfusion strategy | Intervention Type: BEHAVIORAL; Name: Liberal transfusion strategy; Assigned to Arm(s): Liberal | Intervention Type: BEHAVIORAL; Name: Restrictive transfusion strategy; Assigned to Arm(s): Restrictive
B: Arm Label: Liberal Transfusion Strategy; Type: EXPERIMENTAL; Interventions: Biological: Red blood cell transfusion | Arm Label: Restrictive transfusion strategy; Type: EXPERIMENTAL; Interventions: Biological: Red blood cell transfusion | Intervention Type: BIOLOGICAL; Name: Red blood cell transfusion; Assigned to Arm(s): Liberal Transfusion Strategy, Restrictive transfusion strategy
C: Arm Label: Restrictive Transfusion Policy; Type: ACTIVE_COMPARATOR; Interventions: Other: Restrictive transfusion policy | Arm Label: Liberal Transfusion Policy; Type: ACTIVE_COMPARATOR; Interventions: Other: Liberal Transfusion Policy | Intervention Type: OTHER; Name: Restrictive transfusion policy; Assigned to Arm(s): Restrictive Transfusion Policy | Intervention Type: OTHER; Name: Liberal Transfusion Policy; Assigned to Arm(s): Liberal Transfusion Policy
D: Arm Label: Thromboelastography (TEG) level; Type: EXPERIMENTAL; Interventions: Biological: Fresh Frozen Plasma, Biological: Platelets Concentrate, Biological: Cryo Precitipitate | Arm Label: Coagulation Profile; Type: ACTIVE_COMPARATOR; Interventions: Biological: Fresh Frozen Plasma, Biological: Platelets Concentrate, Biological: Cryo Precitipitate | Intervention Type: BIOLOGICAL; Name: Fresh Frozen Plasma; Assigned to Arm(s): Coagulation Profile, Thromboelastography (TEG) level | Intervention Type: BIOLOGICAL; Name: Platelets Concentrate; Assigned to Arm(s): Coagulation Profile, Thromboelastography (TEG) level | Intervention Type: BIOLOGICAL; Name: Cryo Precitipitate; Assigned to Arm(s): Coagulation Profile, Thromboelastography (TEG) level

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-centre, Feasibility, Cluster Randomised Controlled Trial Comparing Restrictive Versus Liberal Blood Transfusion Strategies in Adult Patients Admitted With Acute Upper Gastrointestinal Bleeding
Brief Summary: Aim: To evaluate the feasibility and safety of a restrictive versus liberal red blood cell (RBC) transfusion policy in adult patients admitted with Acute Upper Gastrointestinal Bleeding (AUGIB) in order to inform the design of a definitive phase III randomised controlled trial.


Options:
A: Arm Label: Restrictive Transfusion Policy; Type: ACTIVE_COMPARATOR; Interventions: Other: Restrictive transfusion policy | Arm Label: Liberal Transfusion Policy; Type: ACTIVE_COMPARATOR; Interventions: Other: Liberal Transfusion Policy | Intervention Type: OTHER; Name: Restrictive transfusion policy; Assigned to Arm(s): Restrictive Transfusion Policy | Intervention Type: OTHER; Name: Liberal Transfusion Policy; Assigned to Arm(s): Liberal Transfusion Policy
B: Arm Label: Low transfusion threshold; Type: EXPERIMENTAL; Interventions: Biological: Red blood cell transfusion | Arm Label: High transfusion threshold; Type: ACTIVE_COMPARATOR; Interventions: Biological: Red blood cell transfusion | Intervention Type: BIOLOGICAL; Name: Red blood cell transfusion; Assigned to Arm(s): High transfusion threshold, Low transfusion threshold
C: Arm Label: Allowed drop in hemoglobin to 4.5-5.5 mmol/L; Type: ACTIVE_COMPARATOR; Interventions: Other: Allowed drop in hemoglobin to 4.5-5.5 mmol/L | Arm Label: Allowed drop in hemoglobin to 5.6-6.5 mmol/L; Type: EXPERIMENTAL; Interventions: Other: Allowed drop in hemoglobin to level between 5.6-6.5 mmol/L | Intervention Type: OTHER; Name: Allowed drop in hemoglobin to 4.5-5.5 mmol/L; Assigned to Arm(s): Allowed drop in hemoglobin to 4.5-5.5 mmol/L | Intervention Type: OTHER; Name: Allowed drop in hemoglobin to level between 5.6-6.5 mmol/L; Assigned to Arm(s): Allowed drop in hemoglobin to 5.6-6.5 mmol/L
D: Arm Label: Liberal (10 g/dL) Transfusion Strategy; Type: EXPERIMENTAL; Interventions: Biological: Liberal (10 g/dL) Transfusion Strategy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: Restrictive (Symptomatic) Transfusion Strategy | Intervention Type: BIOLOGICAL; Name: Liberal (10 g/dL) Transfusion Strategy; Assigned to Arm(s): Liberal (10 g/dL) Transfusion Strategy | Intervention Type: BIOLOGICAL; Name: Restrictive (Symptomatic) Transfusion Strategy; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-centre, Feasibility, Cluster Randomised Controlled Trial Comparing Restrictive Versus Liberal Blood Transfusion Strategies in Adult Patients Admitted With Acute Upper Gastrointestinal Bleeding
Brief Summary: Aim: To evaluate the feasibility and safety of a restrictive versus liberal red blood cell (RBC) transfusion policy in adult patients admitted with Acute Upper Gastrointestinal Bleeding (AUGIB) in order to inform the design of a definitive phase III randomised controlled trial.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: red blood cell transfusion | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: red blood cell transfusion | Intervention Type: PROCEDURE; Name: red blood cell transfusion; Assigned to Arm(s): 1, 2
B: Intervention Type: DRUG; Name: Red blood cell transfusion; Assigned to Arm(s): N/A
C: Arm Label: Low transfusion threshold; Type: EXPERIMENTAL; Interventions: Biological: Red blood cell transfusion | Arm Label: High transfusion threshold; Type: ACTIVE_COMPARATOR; Interventions: Biological: Red blood cell transfusion | Intervention Type: BIOLOGICAL; Name: Red blood cell transfusion; Assigned to Arm(s): High transfusion threshold, Low transfusion threshold
D: Arm Label: Restrictive Transfusion Policy; Type: ACTIVE_COMPARATOR; Interventions: Other: Restrictive transfusion policy | Arm Label: Liberal Transfusion Policy; Type: ACTIVE_COMPARATOR; Interventions: Other: Liberal Transfusion Policy | Intervention Type: OTHER; Name: Restrictive transfusion policy; Assigned to Arm(s): Restrictive Transfusion Policy | Intervention Type: OTHER; Name: Liberal Transfusion Policy; Assigned to Arm(s): Liberal Transfusion Policy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open Label, Randomized Phase 3 Clinical Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Brief Summary: The purpose of this study is to find out whether Nivolumab will significantly improve overall survival as compared to therapy of investigator's choice in patients with recurrent or metastatic head and neck carcinoma.


Options:
A: Arm Label: Radiotherapy plus or minus Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Radiotherapy | Arm Label: Transoral Robotic Surgery + Neck Dissection; Type: EXPERIMENTAL; Interventions: Procedure: Transoral Robotic Surgery + Neck Dissection | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): Radiotherapy plus or minus Chemotherapy | Intervention Type: PROCEDURE; Name: Transoral Robotic Surgery + Neck Dissection; Assigned to Arm(s): Transoral Robotic Surgery + Neck Dissection
B: Arm Label: ARM A; Type: EXPERIMENTAL; Interventions: Drug: docetaxel - cisplatin - 5-fluorouracil, Radiation: radiotherapy, Drug: cetuximab | Arm Label: ARM B; Type: ACTIVE_COMPARATOR; Interventions: Drug: cisplatin, Radiation: radiotherapy | Intervention Type: DRUG; Name: docetaxel - cisplatin - 5-fluorouracil; Assigned to Arm(s): ARM A | Intervention Type: RADIATION; Name: radiotherapy; Assigned to Arm(s): ARM A | Intervention Type: DRUG; Name: cetuximab; Assigned to Arm(s): ARM A | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): ARM B | Intervention Type: RADIATION; Name: radiotherapy; Assigned to Arm(s): ARM B
C: Arm Label: Arm A: Nivolumab; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab | Arm Label: Arm B: Cetuximab/Methotrexate/Docetaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cetuximab, Drug: Methotrexate, Drug: Docetaxel | Intervention Type: DRUG; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab | Intervention Type: DRUG; Name: Cetuximab; Assigned to Arm(s): Arm B: Cetuximab/Methotrexate/Docetaxel | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Arm B: Cetuximab/Methotrexate/Docetaxel | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Arm B: Cetuximab/Methotrexate/Docetaxel
D: Intervention Type: BIOLOGICAL; Name: bleomycin sulfate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: fluorouracil; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: leucovorin calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: low-LET cobalt-60 gamma ray therapy; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: low-LET photon therapy; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Optimizing Cognitive Remediation Outcomes in Schizophrenia
Brief Summary: The purpose of this study is to drive an optimal response to neuroplasticity-based cognitive remediation in schizophrenia in order to maximize treatment response. The investigators will investigate factors that have generally been ignored in prior computer-based cognitive remediation programs-those related to social cognition-- and will delineate their relationship to motivation, functional outcome, and the neural substrates of reward anticipation and emotion processing. Current research indicates that, unless the investigators fully understand and harness these factors, the investigators will not achieve meaningful treatment gains for individuals with schizophrenia.


Options:
A: Arm Label: Targeted Cognitive Training; Type: EXPERIMENTAL; Interventions: Other: Targeted Cognitive Training | Arm Label: Social Cognitive Training; Type: EXPERIMENTAL; Interventions: Other: Social Cognitive Training | Intervention Type: OTHER; Name: Targeted Cognitive Training; Assigned to Arm(s): Targeted Cognitive Training | Intervention Type: OTHER; Name: Social Cognitive Training; Assigned to Arm(s): Social Cognitive Training
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Computer games | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Targeted cognitive training (TCT) | Intervention Type: BEHAVIORAL; Name: Targeted cognitive training (TCT); Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Computer games; Assigned to Arm(s): 1
C: Arm Label: Cognitive Remediation; Type: EXPERIMENTAL; Interventions: Drug: Cognitive Remediation | Arm Label: Cognitive activity control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Cognitive Remediation; Assigned to Arm(s): Cognitive Remediation
D: Arm Label: Experimental Treatment; Type: EXPERIMENTAL; Interventions: Other: Computerized plasticity-based adaptive cognitive training | Arm Label: Active Comparator; Type: ACTIVE_COMPARATOR; Interventions: Other: Commercially available computerized training | Intervention Type: OTHER; Name: Computerized plasticity-based adaptive cognitive training; Assigned to Arm(s): Experimental Treatment | Intervention Type: OTHER; Name: Commercially available computerized training; Assigned to Arm(s): Active Comparator

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study MEA117113: Mepolizumab vs. Placebo as Add-on Treatment for Frequently Exacerbating COPD Patients Characterized by Eosinophil Level
Brief Summary: This is a multi-centered, randomized, placebo-controlled, double-blind, parallel group, trial evaluating 2 doses of mepolizumab against placebo given every 4 weeks through subcutaneous (SC) injection. In severe COPD subjects, sputum eosinophils levels are elevated to similar levels as those seen in severe asthmatics. It is hypothesized that the reduction of eosinophils with mepolizumab in COPD subjects would translate into a reduction of COPD exacerbations. The study will evaluate the efficacy and safety of mepolizumab, in subjects who are at or above the baseline blood eosinophil count of at least 150 cells/microliters who exacerbate despite regular use of maximal tolerated therapy, appropriate for severe COPD subjects, in the 12 months prior to study start. In total, 660 subjects will be randomized in 1:1:1 ratio to receive mepolizumab 300 mg, mepolizumab 100mg, or placebo administered SC. The total duration of subject participation will be approximately 62 weeks, consisting of a 1 to 2 week screening period, 52-week treatment period and 8-week follow-up period.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Mepolizumab | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Mepolizumab | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Mepolizumab; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 3
B: Arm Label: mepolizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mepolizumab | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Mepolizumab; Assigned to Arm(s): mepolizumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: Benralizumab Arm A; Type: EXPERIMENTAL; Interventions: Drug: Benralizumab Arm A | Arm Label: Benralizumab Arm B; Type: EXPERIMENTAL; Interventions: Drug: Benralizumab Arm B | Arm Label: Benralizumab Arm C; Type: EXPERIMENTAL; Interventions: Drug: Benralizumab Arm C | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Benralizumab Arm A; Assigned to Arm(s): Benralizumab Arm A | Intervention Type: DRUG; Name: Benralizumab Arm B; Assigned to Arm(s): Benralizumab Arm B | Intervention Type: DRUG; Name: Benralizumab Arm C; Assigned to Arm(s): Benralizumab Arm C | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Benralizumab 100 mg; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab 100 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Benralizumab 100 mg; Assigned to Arm(s): Benralizumab 100 mg

Answer: A